In acute myeloid leukemia (AML), overexpression and constitutive activation of the FLT3 receptor tyrosine kinase induces a strong activation of STAT5, which can be inhibited by an FLT3 protein tyrosine kinase inhibitor [15]. This evidence concerns the gene STAT5A and acute myeloid leukemia.